论文信息 - Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study. - 字舞流文

Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.

M. Kudo | K. Ueshima | M. Moriguchi | M. Ikeda | R. Tateishi | K. Nakao | S. Itoh | H. Aikata | S. Ogasawara | S. Shimose | T. Yamashita | K. Numata | K. Tsuchiya | A. Hiraoka | Hidekatsu Kuroda | Y. Wada | Kouji Yamamoto | Naoya Kato | Yasuhito Tanaka | Y. Kodama